MaaT Pharma Completes a Capital Increase of approximately €12.7 Million with the Support of Current Shareholders

Regulatory News: This press release is not intended for publication or distribution in the United States, Canada, Japan or Australia MaaT Pharma (EURONEXT: MAAT the "Company"), a French clinical-stage

Related Keywords

Australia ,United States ,Canada ,Paris ,France General ,France ,United Kingdom ,French ,Dennis Riedl ,Bpifrance Investissement ,European Parliament ,Financial Services ,Trophic Communications ,Skyviews Life Sciences ,Senior Pr Corporate Communications ,Euronext ,Board Of Directors The Company ,Regulatory News ,Microbiome Ecosystem Therapies ,Seventure Partners ,Maat Pharma ,French Commercial Code ,New Shares ,Capital Increase ,Mutuel Innovation ,Registration Document ,Des March ,Euronext Paris ,Member States ,European Economic Area ,Securities Act ,Markets Act ,Financial Promotion ,Communications Manager ,Medical Communications ,Jamaat ,Dharma ,Ompletes ,Capital ,Increase ,Pproximately ,Billion ,Support ,Current ,Shareholders ,